Moderna just dropped a bombshell: their personalized mRNA cancer vaccine slashed melanoma recurrence risk in a landmark trial — the first time an mRNA vaccine has proven effective at scale. Paired with Merck’s Keytruda, it outperformed the drug alone, hinting at a new era in immunotherapy for solid tumors. Experts are buzzing — this could redefine cancer treatment, especially for high-risk patients. Moderna’s stock surged as investors embraced the breakthrough, which may soon reach patients by next year. While manufacturing hurdles remain and pricing is pending, the promise extends beyond melanoma to lung, breast, and pancreatic cancers — a major leap forward in the fight against cancer.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
